Overview: Cyclosporine A TestIntroduction: The Cyclosporine A Test measures cyclosporine levels to monitor transplant or autoimmune treatment, preventing organ rejection. Aligned with 2023 AST guidelines, it uses chromatography for high sensitivity, aiding in drug monitoring. This test is critical for guiding dosing adjustments, treatment, and improving outcomes in toxicology for patients on cyclosporine therapy.
Other Names: Cyclosporine Assay, Immunosuppressant Monitoring Test.
FDA Status: Laboratory-developed test (LDT), meeting toxicology standards for diagnostic accuracy.
Historical Milestone: Cyclosporine testing began in the 1980s with transplant research. Chromatography methods emerged in the 1990s, and by the 2000s, high-performance liquid chromatography improved accuracy.
Purpose: Monitors cyclosporine levels, guides dosing, and prevents organ rejection or toxicity in patients with transplants or autoimmune diseases.
Test Parameters: 1. Cyclosporine A
Pretest Condition: Fasting for 10-12 hours required to stabilize drug levels. Collect whole blood before the next dose. Report symptoms like tremors or kidney issues, and list medications.
Specimen: 2-5 mL whole blood (EDTA). Transport in a biohazard bag within 8 hours.
Sample Stability at Room Temperature: 8 hours
Sample Stability at Refrigeration: 7 days
Sample Stability at Frozen: 6 months
Medical History: Document transplant history, autoimmune diseases, or symptoms like tremors. Include current medications, especially immunosuppressants.
Consent: Written consent required, detailing the tests purpose, implications for dosing, and potential need for therapy adjustments.
Procedural Considerations: Uses chromatography (e.g., HPLC-MS) to measure cyclosporine levels. Results are available in 1-2 days, enabling rapid clinical decisions.
Factors Affecting Result Accuracy: Non-fasting samples or improper timing can affect results. Hemolysis can degrade samples.
Clinical Significance: Abnormal cyclosporine levels indicate need for dose adjustment to prevent rejection or toxicity. Therapeutic levels support ongoing monitoring.
Specialist Consultation: Consult a transplant specialist or rheumatologist for result interpretation.
Additional Supporting Tests: Kidney function tests, liver function tests, or drug interaction screening to monitor cyclosporine effects.
Test Limitations: Results may vary with drug interactions. Clinical correlation is required.
References: AST Transplant Guidelines, 2023; Transplantation, Kahan BD, 2022.
